Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Alopexx Oncology, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT02151903
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Alopexx Oncology, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01874288
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸St. Jude Hospital Yorba Linda, Fullerton, California, United States
🇺🇸City of Hope, Duarte, California, United States
© Copyright 2025. All Rights Reserved by MedPath